Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

SA Transcripts 161.55K Followers Follow Vir Biotechnology, Inc. ( VIR ) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDT Company Participants Kiki Patel - Head of Investor Relations Marianne De Backer - President, CEO & Director Brent Sabatini - Senior VP, Prin. Accounting Officer, Chief Acct. Officer & Interim Prin. Financial Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division Alec Stranahan - BofA Securities, Research Division Philip Nadeau - TD Cowen, Research Division Etzer Darout - Barclays Bank PLC, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Joseph Stringer - Needham & Company, LLC, Research Division Presentation Operator Hello and welcome to Vir Biotechnology's Second Quarter 2026 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. [Operator Instructions] I will now turn the call over to Kiki Patel, Head of Investor Relations. You may begin, Kiki. Kiki Patel Head of Investor Relations Thank you, Operator, and welcome, everyone. Earlier today, we issued a press release reporting our second quarter 2026 financial results and corporate update. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration outcomes, future results, performance or achievements to differ significantly from those expressed or implied in such forward-looking statements. Forward-looking statements include but are not limited to statements regarding the potential for new therapies to improve awareness, testing and access to care for the chronic hepatitis delta community, the therapeutic and commercial potential of our CHD program, the therapeutic and commercial potential of VIR-5500, and the other clinical and preclinical assets in our oncology solid tumor portfolio as well as the PRO-XTEN masking technology, our development plans and timelines, the potential benefits